Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14120305 | 0.87 | PTPN1 (0.46) | KAT6ACA12CA2CA9ALDH1A1 | |
| SCHEMBL10408548 | 0.86 | ALDH1A1 (0.56) | MAOBCA12CA2CA9PFKFB3 | |
| SCHEMBL297270 | 0.84 | ALDH1A1 (0.62) | KAT6ACA12CA2CA9PFKFB3 | |
| SCHEMBL787675 | 0.83 | CA2 (0.49) | MAOAMAOBKAT6ACA12CA2 | |
| SCHEMBL788431 | 0.81 | MAOA (0.48) | MAOAMAOBCA12CA2CA9 | |
| SCHEMBL14120185 | 0.81 | TAAR1 (0.53) | CA12CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL27990769 | 0.81 | MAOA (0.68) | MAOAMAOBCA12CA2CA9 | |
| SCHEMBL5831675 | 0.81 | PTGS2 (0.56) | MAOAMAOBITGB1ITGA2KAT6A | |
| SCHEMBL3460286 | 0.81 | ITGB1 (0.50) | MAOAMAOBITGB1ITGA2KAT6A | |
| SCHEMBL9996829 | 0.81 | KIF11 (0.54) | CA2PFKFB3PTPN1AGXTNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501772-A | Synthetic method of biphenyl-3-sulfonyl chloride derivative | 上海毕得医药科技股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | MAOA 2190/4885MAOB 2305/4885ITGB1 2856/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | MAOA 4185/4885MAOB 3026/4885ITGB1 2/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | MAOA 2539/4885MAOB 2085/4885ITGB1 1906/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | MAOA 963/4885MAOB 1104/4885ITGB1 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.